Maria Mariana Barros Melo Silveira

Dr. Maria Mariana Barros Melo Silveira

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in The Application of Clinical Genetics
Verified
Journal Article
Open access
PDF file
MSMaria Mariana Barros Melo Silveira
Maria Mariana Barros Melo Silveira
LMLeiliandry de Araújo Melo
Leiliandry de Araújo Melo
FGFilipe Maia Ferreira Gomes
Filipe Maia Ferreira Gomes
LALeonardo José de Cupertino Barreto da Rocha Andrade
Leonardo José de Cupertino Barreto da Rocha Andrade
ISIsabela Paulino Serur
Isabela Paulino Serur
DSDário Celestino Sobral-Filho
Dário Celestino Sobral-Filho
Introduction: Warfarin continues to be the most widely used anticoagulant in clinical practice around the world for the prevention of thromboembolic events in patients with atrial fibrillation (AF). The evaluation of the quality of anticoagulation control, estimated by time in therapeutic range (TTR), is accepted as a good method to evaluate the quality of anticoagulation. The variability of TTR can be explained by the presence of variants of the CYP2C9 and VKORC1 genes. Methods: This study examined the association between polymorphisms of the CYP2C9 and VKORC1 genes and control of oral anticoagulation, through TTR, in patients with AF. A cross-sectional study was conducted within a cohort follow-up. The study comprised of 317 patients with AF, using warfarin, who were followed up for one year. The genotyping of genes CYP2C9 (rs1057910), (rs1799853) and VKORC1 (rs923231) was performed by PCR in real time, using TaqMan probes. Results: Patients who had variant genotypes for the CYP2C9*3 gene (rs1057910) presented higher TTR (TTR 81-100%) when compared to when compared to the <45% and 46-60% TTR groups (p=0.005 and p=0.002, respectively). Regarding VKORC1 (rs923231), patients who had the variant genotype for the VKORC1 (rs923231) gene also presented a higher TTR (TTR 81-100%), when when compared to the <45% and 46-60% TTR groups (p=0.005 and p=0.004, respectively). In a multivariate model, VKORC1 (rs923231) remained associated for comparisons with the TTR groups (<45% vs 81-100% groups, p=0.01; and 46-60% vs 81-100% groups, p=0.01). Conclusion: The genotypes of the CYP2C9*3 (AA) and VKORC1 -1639 (GG) genes were associated with the worst quality of anticoagulation control (TTR) in patients with AF using warfarin in the northeast of Brazil.

1 May 2018 in Avances en Enfermería
Verified
Journal Article
Open access
PDF file
TFThaisa Figueiredo
Thaisa Figueiredo
CCChristefany Régia Braz Costa
Christefany Régia Braz Costa
MSMaria Mariana Barros Melo Silveira
Maria Mariana Barros Melo Silveira
HAHirla Vanessa Soares De Araújo
Hirla Vanessa Soares De Araújo
TSTâmara Silva
Tâmara Silva
SBSimone Maria Muniz da Silva Bezerra
Simone Maria Muniz da Silva Bezerra
Objetivo: investigar la adherencia farmacológica y el conocimiento de pacientes en tratamiento con anticoagulantes orales con acompañamiento en ambulatorio. Método: estudio transversal con enfoque cuantitativo. Resultados: se evaluaron 222 pacientes; de ellos el 60,8 % se clasificaron como no adherentes, y el 63,1 % poseían conocimiento inadecuado sobre la anticoagulación oral. La no adhesión estaba relacionada con un tratamiento más prolongado (p < 0,001) y con los pacientes con valores da International Normalized Ratio (inr) fuera del rango terapéutico (p = 0,022). El conocimiento no adecuado se asoció al menor nivel educativo (p < 0,001), al sedentarismo (p = 0,027), al menor tiempo de acompañamiento en ambulatorio (p < 0,001) y a los pacientes con valores de inr fuera del rango terapéutico (p = 0,012 ). Conclusión: con base en los resultados se evidencia la necesidad de estrategias de educación en salud que atiendan a ese público, teniendo en cuenta la comprensión individual y la adhesión farmacológica como algo crucial en la terapia.

1 January 2020 in Journal of Clinical Medicine Research
Verified
Journal Article
Open access
PDF file
MSMaria Mariana Barros Melo Silveira
Maria Mariana Barros Melo Silveira
JCJoao Victor Batista Cabral
Joao Victor Batista Cabral
BSBruno de Melo Souza
Bruno de Melo Souza
LHLouis Hussein Patu Hazime
Louis Hussein Patu Hazime
SASara Larissa de Melo Araujo
Sara Larissa de Melo Araujo
DODinaldo Cavalcanti de Oliveira
Dinaldo Cavalcanti de Oliveira
Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation.J Clin Med Res. 2020;12(10):647-654doi: https://doi.org/10.14740/jocmr4313

29 June 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
MSMaria Mariana Barros Melo Silveira
Maria Mariana Barros Melo Silveira
João Victor Batista CabralJoão Victor Batista Cabral
João Victor Batista Cabral
AXAmanda Tavares Xavier
Amanda Tavares Xavier
LCLucas Reis da Costa
Lucas Reis da Costa
DNDhouglas José Ferreira Do Nascimento
Dhouglas José Ferreira Do Nascimento
DODinaldo Cavalcanti de Oliveira
Dinaldo Cavalcanti de Oliveira

16 September 2023 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MSMaria Mariana Barros Melo Silveira
Maria Mariana Barros Melo Silveira
João Victor Batista CabralJoão Victor Batista Cabral
João Victor Batista Cabral
AXAmanda Tavares Xavier
Amanda Tavares Xavier
KÓKleyton Palmeira Do Ó
Kleyton Palmeira Do Ó
JJJulio Francisco de Moura Junior
Julio Francisco de Moura Junior
DODinaldo Cavalcanti de Oliveira
Dinaldo Cavalcanti de Oliveira

1 March 2021 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
João Victor Batista CabralJoão Victor Batista Cabral
João Victor Batista Cabral
MSMaria Mariana Barros Melo Silveira
Maria Mariana Barros Melo Silveira
AXAmanda Tavares Xavier
Amanda Tavares Xavier
NANorma de Assunção
Norma de Assunção
DSDário Celestino Sobral-Filho
Dário Celestino Sobral-Filho
DODinaldo Oliveira
Dinaldo Oliveira
OBJECTIVE: Triggering receptor expressed on myeloid cells-1 concentration can be used as a predictive, diagnostic, and prognostic marker in patients with sepsis. The objective of this study was to determine the validity of triggering receptor expressed on myeloid cells-1 levels as a biomarker of sepsis in pediatric patients. METHODS: This was an integrative literature review. PubMed, ScienceDirect, LILACS, MEDLINE, and VHL databases were searched for papers published between 2015 and 2020, using the keywords triggering receptor expressed on myeloid cells-1, sepsis, and child. RESULTS: The review included ten studies, of which four used triggering receptor expressed on myeloid cells-1 as a predictive biomarker; four, as a diagnostic biomarker; and two, as a prognostic biomarker. A total of 1,409 and 1,628 patients were included in primary and review studies, respectively. There was a predominance of significant results for the validity of triggering receptor expressed on myeloid cells-1 levels in the prediction, diagnosis, and prognosis of sepsis in pediatric patients. CONCLUSIONS: Triggering receptor expressed on myeloid cells-1 is a valid predictive, diagnostic, and prognostic biomarker of sepsis with good sensitivity and specificity in the pediatric population.